Soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1) is Decreased in Lung Cancer Patients Showing Progression: A Pilot Study

REFERENCES

• Boring C. C., Squires T. S., Tong T., Montgomery S. Cancer Statistics, 1994. CA Cancer J. Clin. 1994; 44(1)7–26
   PubMed Web of Science ®Google Scholar
• Brattstrom D., Bergqvist M., Hesselius P., Larsson A., Lamberg K., et al. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumors and poorer survival in non-small cell lung cancer patients. Lung Cancer 2002; 37(1)57–63
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis. Adv. Cancer Res. 1985; 43: 175–203
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971; 285(21)1182–1186
   PubMed Web of Science ®Google Scholar
• Ferrara N., Alitale K. Clinical application of angiogenic growth factors and their inhibitors. Nat. Med. 1999; 12(5)1359–1364
   Google Scholar
• Toi M., Matsumato T., Bando H. Vascular endothelial growth factor; its prognostic, predictive and therapeutic implications. Lancet Oncol. 2001; 2(11)667–673
   PubMed Web of Science ®Google Scholar
• Merrick D. T., Haney J., Petrunich S., Sugita M., Miller Y. E., et al. Overexpression of vascular endothelial growth factor and its receptors in bronchial dypslasia demonstrated by quantitative RT-PCR analysis. Lung Cancer 2005; 48(1)31–45
   PubMed Web of Science ®Google Scholar
• Veikolla T., Karkkainen M., Claesson-Welsh L., Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000; 60(2)203–212
   PubMed Web of Science ®Google Scholar
• Shibuya M., Ito N., Claesson-Welsh L. Structure and function of vascular endothelial growth factor receptor -1 and -2. Curr. Top. Microbiol. Immunol. 1999; 237: 59–83
   PubMed Web of Science ®Google Scholar
• Partanen T. A., Alitalo K., Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 1999; 86(11)2406–2412
   PubMed Web of Science ®Google Scholar
• Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (t) closely related to the fms family. Oncogene 1990; 5(4)519–524
   PubMed Web of Science ®Google Scholar
• Olofsson B., Korpelainen E., Pepper M. S., Mandriota S. J., Aase K., et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad. Sci. USA 1998; 95(20)11709–11714
   PubMed Web of Science ®Google Scholar
• Kendall R. L., Thomas K. A. Inhibition of vascular endothelial cell growth activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 1993; 90(22)10705–10709
   PubMed Web of Science ®Google Scholar
• Kendall R. L., Wang G., Thomas K. A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 1996; 226(2)324–328
   PubMed Web of Science ®Google Scholar
• Roeckl W., Hecht D., Sztajer H., Waltenberger J., Yayon A., Weich H. A. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp. Cell Res. 1998; 241(1)161–170
   PubMed Web of Science ®Google Scholar
• He Y., Smith S. K., Day K. A., Clark D. E., Licence D. R., Charnock-Jones D. S. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol. Endocrinol. 1999; 13(4)537–545
   PubMed Web of Science ®Google Scholar
• Koga K., Osuga Y., Yoshino O., Hirota Y., Ruimeng X., Hirata T., et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J. Clin. Endocrinol. Metab. 2003; 88(5)2348–2351
   PubMed Web of Science ®Google Scholar
• Barleon B., Hauser S., Schollmann C., Weindel K., Marme D., Yayon A., Weich H. A. Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells. J. Cell Biochem. 1994; 54(1)56–66
   PubMed Web of Science ®Google Scholar
• Barleon B., Sozzani S., Zhou D., Weich H. A., Mantovani A., Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87(8)3336–3343
   PubMed Web of Science ®Google Scholar
• Ishida A., Murray J., Saito Y., Kanthou C., Benzakour O., Shibuya M., Wijelath E. S. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J. Cell Physiol. 2001; 188(3)359–368
   PubMed Web of Science ®Google Scholar
• Volm M., Koomagi R., Mattern J., Stammler G. Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. Anticancer Res. 1997; 17(1A)99–103
   PubMed Web of Science ®Google Scholar
• Aliello L. P., Pierce E. A., Foley E. D., Takagi H., Chen H., et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA 1995; 92(23)10457–10461
   PubMed Web of Science ®Google Scholar
• Kong H.-L., Hecht D., Song W., Kovesdi I., Hackett N. R., Yayon A., Crystal G. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum. Gene Ther. 1998; 9(6)823–833
   PubMed Web of Science ®Google Scholar
• Goldman C. K., Kendall R. L., Cabrera G., Soroceanu L., Heike Y., et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. USA 1998; 95(15)8795–8800
   PubMed Web of Science ®Google Scholar
• Wilhelm L., Kolesar J. M. Role of adjuvant chemotherapy in the treatment of non-small-cell lung cancer. Am. J. Health-Syst. Pharm. 2005; 62(13)1365–1369
   PubMed Web of Science ®Google Scholar
• Ogawa T., Takayama K., Takakura N., Kitano S., Ueno H. Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther. 2002; 9(8)633–640
   PubMed Web of Science ®Google Scholar
• Dikov M. M., Ohm J. E., Ray N., Tchekneva E. E., Burlison J., et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J. Immunol. 2005; 174(1)215–222
   PubMed Web of Science ®Google Scholar
• Volm M., Koomagi R., Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int. J. Cancer. 1997; 74(1)64–68
   PubMed Web of Science ®Google Scholar
• Belgore F. M., Lip G. Y., Blann A. D. Vascular endothelial growth factor and its receptor, Flt-1, in smokers and non-smokers. Br. J. Biomed. Sci. 2000; 57(3)207–213
   PubMed Web of Science ®Google Scholar
• Schmidt-Lucke C., Belgore F., Reinhold D., Ansorge S., Klein H. U., Schmidt-Lucke J. A., Lip G. Y.H. Soluble vascular endothelial growth factor, soluble VEGF receptor Flt-1 and endothelial function in healthy smokers. Int. J. Cardiol. 2005; 100(2)207–212
   PubMed Web of Science ®Google Scholar
• Decaussin M., Sartelet H., Robert C., Moro D., Claraz C., Brambilla C., Brambilla E. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J. Pathol. 1999; 188(4)369–377
   PubMed Web of Science ®Google Scholar
• Ilhan N., Ilhan N., Deveci F. Functional significance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types. Clin. Biochem. 2004; 37(9)840–845
   PubMed Web of Science ®Google Scholar
• Swidzińska E., Ossolińska M., Naumnik W., Izycki T., Kucejko W., Chyczewska E. Circulating VEGF and its soluble receptor sVEGFR-1 in patients with lung cancer. Pneumonol. Alergol. Pol. 2004; 72(9–10)389–394
   PubMedGoogle Scholar
• Kramer G., Erdal H., Mertens H. J., Nap M., Mauermann J., et al. Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18. Cancer Res. 2004; 64(5)1751–1756
   PubMed Web of Science ®Google Scholar
• Gibb R. K., Taylor D. D., Wan T., O'Connor D. M., Doering D. L., Gercel-Taylor C. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. Gynecol. Oncol. 1997; 65(1)13–22
   PubMed Web of Science ®Google Scholar